175 related articles for article (PubMed ID: 31043681)
21. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.
Zhang H; Hylander BL; LeVea C; Repasky EA; Straubinger RM; Adjei AA; Ma WW
Br J Cancer; 2014 Jan; 110(2):320-9. PubMed ID: 24327018
[TBL] [Abstract][Full Text] [Related]
22. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
23. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
24. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
25. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
26.
Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
[TBL] [Abstract][Full Text] [Related]
27. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D; Bhin J; Yemelyanenko J; Kas SM; Rolfs F; Lutz C; Lee JK; Klarenbeek S; Silverman IM; Annunziato S; Chan CS; Piersma SR; Eijkman T; Badoux M; Gogola E; Siteur B; Sprengers J; de Klein B; de Goeij-de Haas RR; Riedlinger GM; Ke H; Madison R; Drenth AP; van der Burg E; Schut E; Henneman L; van Miltenburg MH; Proost N; Zhen H; Wientjens E; de Bruijn R; de Ruiter JR; Boon U; de Korte-Grimmerink R; van Gerwen B; Féliz L; Abou-Alfa GK; Ross JS; van de Ven M; Rottenberg S; Cuppen E; Chessex AV; Ali SM; Burn TC; Jimenez CR; Ganesan S; Wessels LFA; Jonkers J
Nature; 2022 Aug; 608(7923):609-617. PubMed ID: 35948633
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Arai Y; Totoki Y; Hosoda F; Shirota T; Hama N; Nakamura H; Ojima H; Furuta K; Shimada K; Okusaka T; Kosuge T; Shibata T
Hepatology; 2014 Apr; 59(4):1427-34. PubMed ID: 24122810
[TBL] [Abstract][Full Text] [Related]
29. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
30. FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.
Sridharan V; Neyaz A; Chogule A; Baiev I; Reyes S; Barr Fritcher EG; Lennerz JK; Sukov W; Kipp B; Ting DT; Deshpande V; Goyal L
Clin Cancer Res; 2022 Dec; 28(24):5431-5439. PubMed ID: 36190545
[TBL] [Abstract][Full Text] [Related]
31. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Krook MA; Bonneville R; Chen HZ; Reeser JW; Wing MR; Martin DM; Smith AM; Dao T; Samorodnitsky E; Paruchuri A; Miya J; Baker KR; Yu L; Timmers C; Dittmar K; Freud AG; Allenby P; Roychowdhury S
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371345
[TBL] [Abstract][Full Text] [Related]
32. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
33. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
34. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
[TBL] [Abstract][Full Text] [Related]
36. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
Tanizaki J; Ercan D; Capelletti M; Dodge M; Xu C; Bahcall M; Tricker EM; Butaney M; Calles A; Sholl LM; Hammerman PS; Oxnard GR; Wong KK; Jänne PA
Cancer Res; 2015 Aug; 75(15):3139-46. PubMed ID: 26048680
[TBL] [Abstract][Full Text] [Related]
37. FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Milton CI; Selfe J; Aladowicz E; Man SYK; Bernauer C; Missiaglia E; Walters ZS; Gatz SA; Kelsey A; Generali M; Box G; Valenti M; de Haven-Brandon A; Galiwango D; Hayes A; Clarke M; Izquierdo E; Gonzalez De Castro D; Raynaud FI; Kirkin V; Shipley JM
Mol Oncol; 2022 Mar; 16(6):1272-1289. PubMed ID: 34850536
[TBL] [Abstract][Full Text] [Related]
38. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.
Tchaicha JH; Akbay EA; Altabef A; Mikse OR; Kikuchi E; Rhee K; Liao RG; Bronson RT; Sholl LM; Meyerson M; Hammerman PS; Wong KK
Cancer Res; 2014 Sep; 74(17):4676-84. PubMed ID: 25035393
[TBL] [Abstract][Full Text] [Related]
39. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
[TBL] [Abstract][Full Text] [Related]
40. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
